Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Felodipine Extended-release Tablets USP 2.5mg, 5mg, and 10mg. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India.
Felodipine extended-release tablets USP 2.5mg, 5mg, and 10mg is the generic equivalent of AstraZeneca’s Plendil Extended-release Tablets, 2.5mg, 5mg and 10mg and indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
The annual sale of the product is approximately $64 million for the twelve months ending March 2012 according to IMS. Aurobindo now has a total of 172 ANDA approvals (147 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1823.00 |
Dr. Reddys Lab | 1347.85 |
Cipla | 1479.80 |
Lupin | 2179.75 |
Zydus Lifesciences | 977.20 |
View more.. |